# US 2024/0197872 A1 · Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197872 A1
- Document ID: US20240197872A1
- Status: Published application
- Kind: A1
- Application number: 18/286,286
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Acepodia Biotechnologies Ltd.
- Applicants: Acepodia Biotechnologies Ltd.
- Inventors: CHING-WEN HSIAO; ZIH-FEI CHENG; TAI-SHENG WU; HAO-KANG LI; HSIU-PING YANG; CHIA-YUN LEE; SAI-WEN TANG; YI-HUNG OU; YAN-LIANG LIN; SHIH-CHIA HSIAO
- Web page: https://patentgrep.com/patent/US20240197872A1

## CPC

- A61K 40/33: Antibodies; T-cell engagers
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4221: {CD20}
- A61P 35/00: Antineoplastic agents
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 5/0636: {T lymphocytes}
- C12N 2500/84: from mammals
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2502/115: Platelets, megakaryocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are novel compositions enriched in gdT cells with high therapeutic potential. Methods to produce such compositions and methods of uses thereof in adoptive immunotherapies are also provided.

## Claims

### Claim 1

A method of manufacturing a cell population enriched in gamma delta T (gdT) cells, comprising culturing a source cell population comprising gdT cells in a medium supplemented with (i) a phosphoantigen, (ii) a cytokine, and (iii) human platelet lysate (“HPL”).

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell population is not contacted with a feeder cell or tumor cell during the culture.

### Claim 3 (depends on 1)

The method of claim 1 that does not include positively selecting for gdT cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell population is cultured for 3 to 40 days, 4 to 40 days, 5 to 40 days, 6 to 40 days, 7 to 40 days, 10 to 40 days, 10 to 30 days, 6 to 20 days, 12 to 20 days, or 14 to 18 days.

### Claim 5 (depends on 1)

The method of claim 1, further comprising depleting alpha beta T (abT) cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the abT cells are depleted around the half-time of the culture.

### Claim 7 (depends on 5)

The method of claim 5, wherein the cells are cultured for 14 to 18 days and the abT cells are depleted between Day 4 and Day 10.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cytokine is replenished during the culture.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cytokine is replenished once per week, twice per week, three times per week, every other day, or daily.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cytokine is interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), interleukin-33 (IL-33), or any combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cytokine is IL-2.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cytokine is supplemented at a concentration of 200-3000 IU/mL.

### Claim 13 (depends on 1)

The method of claim 1, wherein the phosphoantigen is not replenished during the culture.

### Claim 14 (depends on 1)

The method of claim 1, wherein the phosphoantigen is a bisphosphonate selected from the group consisting of clodronate, etidronate, alendronate, pamidronate, zoledronate (zoledronic acid), neridronate, ibandronate, and pamidronate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the phosphoantigen is zoledronate.

### Claim 16 (depends on 1)

The method of claim 1, wherein the phosphoantigen is selected from the group consisting of bromohydrin pyrophosphate (BrHPP), 4-hydroxy-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP), and dimethylallyl pyrophosphate (DMAPP).

### Claim 17 (depends on 1)

The method of claim 1, wherein the phosphoantigen is supplemented at a concentration of 0.1-20 μM.

### Claim 18 (depends on 1)

The method of claim 1, wherein the HPL is supplemented at a concentration of 1-20 vol %.

### Claim 19 (depends on 1)

The method of claim 1, wherein the medium comprises glucose at a concentration of 600-5000 mg/L.

### Claim 20 (depends on 1)

The method claim 1, wherein the medium is a serum-free medium.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cell population is cultured in a device containing an air-permeable surface.

### Claim 22 (depends on 21)

The method of claim 21, wherein the device is a G-Rex device.

### Claim 23 (depends on 1)

The method of claim 1, wherein the source cell population comprises peripheral blood mononuclear cells (PBMCs), bone marrow, umbilical cord blood, or a combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the source cell population comprises PBMCs.

### Claim 25 (depends on 24)

The method of claim 24, further comprising obtaining the PBMCs from peripheral blood.

### Claim 26 (depends on 1)

The method of claim 1, wherein the gdT cells in the source cell population are expanded for at least 1,000 fold during the culture.

### Claim 27 (depends on 1)

The method of claim 1, wherein at least 75% of the resulting cell population are gdT cells.

### Claim 28 (depends on 1)

The method of claim 1, further comprising adding a targeting moiety to the surface of the cells in the resulting cell population.

### Claim 29 (depends on 28)

The method of claim 28, wherein the targeting moiety is complexed to the cell surface via the interaction between a first linker conjugated to the targeting moiety and a second linker conjugated to the cell surface.

### Claim 30 (depends on 28)

The method of claim 28, wherein the targeting moiety is exogenously expressed.

### Claim 31 (depends on 1)

The method of claim 1, further comprising cryopreserving the cell population after the culture.

### Claim 32 (depends on 1)

A population of cells obtained by the method of claim 1.

### Claim 33

A population of cells comprising at least 70% gdT cells, wherein (1) the gdT cells express at least 400 DNAM-1 molecules per cell on average; (2) at least 30% of the gdT cells are CD69+; or both (1) and (2).

### Claim 34 (depends on 33)

The population of cells of claim 33, wherein the gdT cells express at least 500, at least 1000, at least 2000, or at least 3000 DNAM-1 molecules per cell on average.

### Claim 35 (depends on 33)

The cell population of claim 33, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% of the gdT cells are CD69+.

### Claim 36 (depends on 33)

The cell population of claim 33, wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the gdT cells are terminally differentiated effector (TDEM) cells.

### Claim 37 (depends on 33)

The cell population of claim 33, comprising at least 1×106, at least 5×106, at least 1×107, at least 5×107, at least 1×108, at least 5×108, at least 1×109, at least 5×109, at least 1×1010, at least 5×1010, or at least 1×1011 gdT cells.

### Claim 38 (depends on 33)

The cell population of claim 33, wherein the cell population has not been positively selected for gdT cells.

### Claim 39 (depends on 33)

The cell population of claim 33, where the cell population has been cultured for 20 days or less since the source cell population from which the cell population is derived or obtained from a single donor.

### Claim 40 (depends on 33)

The cell population of claim 33, wherein:
(1) the gdT cells express at least 400 CD56 molecules per cell on average;
(2) the gdT cells express at least 400 CD16 molecules per cell on average;
(3) the gdT cells express at least 400 NKG2D molecules per cell on average;
(4) the gdT cells express at least 400 CD107a molecules per cell on average;
(5) the gdT cells express at most 2800 PD-1 molecules per cell on average;
(6) the gdT cells express at least 5000 DNAM-1 molecules per cell on average;
(7) the gdT cells express at least 400 CD69 molecules per cell on average; or
(8) the gdT cells express at least 100 Granzyme B molecules per cell on average;
or any combination thereof.

### Claim 41 (depends on 33)

The cell population of claim 33, wherein at least 30% of the gdT cells are Vδ2 T cells.

### Claim 42 (depends on 33)

The cell population of claim 33, wherein at least 10% of the gdT cells comprise a targeting moiety complexed to the cell surface.

### Claim 43 (depends on 42)

The cell population of claim 42, wherein the targeting moiety is not a nucleic acid.

### Claim 44 (depends on 42)

The cell population of claim 42, wherein the targeting moiety is an antibody or antigen binding unit that specifically binds to a biological marker on a target cell.

### Claim 45 (depends on 44)

The cell population of claim 44, wherein the biological marker is a tumor antigen.

### Claim 46 (depends on 44)

The cell population of claim 44, wherein the gdT cells express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) that comprises the antibody or antigen binding fragment.

### Claim 47 (depends on 42)

The cell population of claim 42, wherein the targeting moiety is not produced by the gdT cells.

### Claim 48 (depends on 42)

The cell population of claim 42, wherein the targeting moiety is complexed to the cell surface via the interaction between a first linker conjugated to the targeting moiety and a second linker conjugated to the cell surface.

### Claim 49 (depends on 48)

The cell population of claim 48, wherein the first linker is a first polynucleotide, and the second linker is a second polynucleotide.

### Claim 50 (depends on 49)

The cell population of claim 49, wherein (1) the first polynucleotide has 4 to 500 nucleotides, (2) the second polynucleotide has 4 to 500 nucleotides, or both (1) and (2).

### Claim 51 (depends on 32)

The cell population of claim 32 that is cryopreserved.

### Claim 52 (depends on 32)

A pharmaceutical composition comprising the cell population of claim 32 and a pharmaceutically acceptable carrier.

### Claim 53 (depends on 32)

The cell population of claim 32, that can maintain its therapeutic potency after being stored at or below 0° C. for at least one week, at least two weeks, at least 1 month, at least 3 months, or at least 6 months.

### Claim 54 (depends on 32)

Use of the cell population or the pharmaceutical composition of claim 32 in an adoptive immunotherapy.

### Claim 55 (depends on 32)

Use of the cell population or the pharmaceutical composition of claim 32 in the treatment of a disease or disorder.

### Claim 56 (depends on 32)

A method of treating a disease or disorder in a subject in need thereof, comprising administering the cell population or the pharmaceutical composition of claim 32 to the subject.

### Claim 57 (depends on 55)

The use of claim 55, wherein the disease or disorder is tumor or cancer.

### Claim 58 (depends on 55)

The use of claim 55, wherein the disease or disorder is an autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, a pathogenic disease, HIV or other viral infection, fungal infection, protozoan infection, or bacterial infection.

### Claim 59 (depends on 56)

The method of claim 56, wherein the subject is human.
